A Phase I/II Study Evaluating the Maximum Tolerated Dose, Bioequivalence/Pharmacokinetics, Safety, and Efficacy of Hyperthermia and ThermoDox (Lyso-Thermosensitive Liposomal Doxorubucin) in Patients With Local-Regional Recurrent Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Advanced breast cancer
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms DIGNITY; US DIGNITY
- Sponsors Celsion Corporation
- 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2015 Results were published in a Celsion Corporation media release.
- 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium 2015.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History